Buoyed by semaglu­tide suc­cess, No­vo Nordisk un­corks plans for $2.58B man­u­fac­tur­ing ex­pan­sion in Den­mark

No­vo Nordisk scored a pair of dou­ble wins the last cou­ple years with the ap­proval of two dif­fer­ent forms of semaglu­tide, the com­pa­ny’s newest block­buster prod­uct line. Now, No­vo is set­ting aside a se­ri­ous pile of cash to take its man­u­fac­tur­ing ops in­to the fu­ture as the com­pa­ny looks to lev­el up.

No­vo will in­vest rough­ly $2.58 bil­lion (DKK 17 bil­lion) to great­ly ex­pand its man­u­fac­tur­ing foot­print at its cen­tral hub in Kalund­borg, Den­mark, with three new fa­cil­i­ties and the ex­pan­sion of a fourth on the way, the com­pa­ny said this week.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER